journal
https://read.qxmd.com/read/37038365/abacavir-safety-and-effectiveness-in-young-infants-with-hiv-in-south-african-observational-cohorts
#21
JOURNAL ARTICLE
Reneé de Waal, Helena Rabie, Karl-Günter Technau, Brian Eley, Nosisa Sipambo, Mark Cotton, Andrew Boulle, Robin Wood, Frank Tanser, Geoffrey Fatti, Matthias Egger, Mary-Ann Davies
BACKGROUND: WHO guidelines recommend abacavir in first-line antiretroviral treatment for children and neonates. However, there is no approved dose <3 months of age, and data in neonates are limited. METHODS: We included infants who initiated ART aged <3 months, between 2006 and 2019, in nine South African cohorts. In those who received abacavir or zidovudine, we described antiretroviral discontinuation rates; and 6- and 12-month viral suppression (<400 copies/mL)...
February 2023: Antiviral Therapy
https://read.qxmd.com/read/36896821/treatment-related-early-discontinuations-and-adverse-events-among-newly-diagnosed-people-living-with-hiv-initiating-integrase-inhibitors-in-a-real-world-setting
#22
JOURNAL ARTICLE
Charlotte-Paige Rolle, Jamie Castano, Vu Nguyen, Kiran Patel, Federico Hinestrosa, Edwin DeJesus
BACKGROUND: Cohort studies suggest higher discontinuation rates with integrase strand transfer inhibitors (INSTIs) than are seen in clinical trials. We assessed discontinuations and adverse events (AEs) that were considered related to the initial INSTI in the first year following initiation among treatment-naïve people living with HIV (PLWH). METHODS: Newly diagnosed PLWH initiating raltegravir, elvitegravir/cobicistat, dolutegravir or bictegravir in combination with emtricitabine/tenofovir alafenamide or emtricitabine/tenofovir disoproxil fumarate between 10/2007 and 1/2020 at the Orlando Immunology Center were included...
February 2023: Antiviral Therapy
https://read.qxmd.com/read/36861651/case-report-and-literature-review-a-hiccup-patient-developed-encephalitis-and-duodenal-perforation
#23
JOURNAL ARTICLE
Fanfeng Kong, Xiao Xue Zeng
Brainstem encephalitis is rare and this study aims to report the clinical course, imaging features, and therapeutic response of hiccup patient with gastric ulcer who developed brainstem encephalitis with Epstein-Barr virus (EBV) detected in cerebrospinal fluid and then subsequently followed by development of duodenal perforation. Data of a gastric ulcer patient who suffered from hiccups, with brainstem encephalitis detected and then subsequently suffered from duodenal perforation were collected retrospectively and analyzed...
February 2023: Antiviral Therapy
https://read.qxmd.com/read/36802921/efficacy-safety-and-tolerability-of-biktarvy-in-hiv-1-infection-a-scoping-review
#24
REVIEW
Ellen Peters, And Collins Iwuji
Background:  Biktarvy is approved for use in HIV-1 infection in both treatment-naïve and treatment-experienced individuals, after a series of successful phase III trials. However, studies on real-world evidence on its efficacy, safety and tolerability are limited. Purpose:  The study aims to collate real-world evidence on the use of Biktarvy in clinical practice to identify gaps in knowledge. Research Design:  Scoping review was undertaken using PRISMA guidelines and a systematic search strategy...
February 2023: Antiviral Therapy
https://read.qxmd.com/read/36724136/inhibition-of-chikungunya-virus-replication-by-n-%C3%AF-chloroacetyl-l-ornithine-in-c6-36-vero-cells-and-human-fibroblast-bj
#25
JOURNAL ARTICLE
Lucero Rojas-Luna, Araceli Posadas-Modragón, Amanda M Avila-Trejo, Verónica Alcántara-Farfán, Lorena I Rodríguez-Páez, José Angel Santiago-Cruz, Marvin O Pastor-Alonso, J Leopoldo Aguilar-Faisal
BACKGROUND: Polyamines are involved in several cellular processes and inhibiting their synthesis affects chikungunya virus (CHIKV) replication and translation, and, therefore, reduces the quantity of infectious viral particles produced. In this study, we evaluated the inhibition of CHIKV replication by N-ω-chloroacetyl-L-ornithine (NCAO), a competitive inhibitor of ornithine decarboxylase, an enzyme which is key in the biosynthesis of polyamines (PAs). METHODS: The cytotoxicity of NCAO was evaluated by MTT in cell culture...
February 2023: Antiviral Therapy
https://read.qxmd.com/read/36691849/population-pharmacokinetic-pharmacodynamic-models-of-jnj-64794964-a-toll-like-receptor-7-agonist-in-healthy-adult-participants
#26
JOURNAL ARTICLE
Liviawati S Wu, Yue Hu, Edward J Gane, Leen Slaets, An De Creus, Yanhua Ding, Junqi Niu, Christian Schwabe, Nele Goeyvaerts, Zhongnan Xu, Dandan Huo, Marianne Tuefferd, Inge Verbrugge, Pieter Van Remoortere, Ullrich Schwertschlag, Joris Vandenbossche
BACKGROUND: JNJ-4964 is a TLR7 agonist, which, via a type I interferon (IFN)-dependent mechanism, may enhance host immunity suppressed by persistent exposure to hepatitis B antigens in chronic hepatitis B. METHODS: PK and PD data were pooled from 2 studies involving 90 participants ( n = 74 JNJ-4964, dose range 0.2-1.8 mg; n = 16 placebo) in a fasted state. Food effects on PK were studied in 24 participants (1.2 or 1.25 mg). A population PK model and PK/PD models were developed to characterize the effect of JNJ-4964 plasma levels on the time course of IFN-α, IFN-γ-inducible protein 10 (IP-10 or CXCL10), IFN-stimulated gene 15 ( ISG15 ), neopterin and lymphocytes following single and weekly dosing in healthy adults...
February 2023: Antiviral Therapy
https://read.qxmd.com/read/36609161/pharmacokinetics-of-zanamivir-in-critically-ill-patients-undergoing-continuous-venovenous-hemofiltration
#27
JOURNAL ARTICLE
André Wieringa, Peter Gj Ter Horst, GertJan Hj Wagenvoort, Birgit Cp Koch, Jasper J Haringman
BACKGROUND: Limited data exist for dosing of zanamivir in the setting of CVVH in the intensive care unit (ICU). Our objective is to report the pharmacokinetics and sieving coefficient (Sv ) of zanamivir in patients receiving continuous venovenous hemofiltration (CVVH). METHODS: In this prospective observational study, patients of ≥18 years admitted to the ICU with a life-threatening Influenza A or B infection, treated with zanamivir i.v. undergoing CVVH were included...
February 2023: Antiviral Therapy
https://read.qxmd.com/read/36542553/a-favipiravir-induced-angioedema-and-urticaria-in-a-covid-19-patient
#28
JOURNAL ARTICLE
Figen Ergur Ozturk, Ayperi Ozturk, Hale Ates
Although favipiravir is a promising drug for coronavirus disease 2019, some adverse effects, including skin lesions, have been reported. A 56-year-old female who was prescribed favipiravir by a filiation team following a positive severe acute respiratory syndrome coronavirus 2 polymerase chain reaction test presented to our hospital. After examination, favipiravir and paracetamol were prescribed. She represented to the hospital with facial swelling and itchy rashes on her forearm. Angioedema and urticaria were diagnosed...
December 2022: Antiviral Therapy
https://read.qxmd.com/read/36495070/understanding-the-effect-of-direct-acting-antiviral-therapy-on-weight-in-patients-with-chronic-hepatitis-c
#29
JOURNAL ARTICLE
Chinyere L Nkwocha, Pamela S Carter, Somer Blair, James M Blackwell, Esther O Fasanmi
BACKGROUND: Direct-acting antivirals (DAAs) have revolutionized treatment for HCV. Compared to interferon-based therapies, DAAs achieve higher rates of sustained virologic response, with more tolerable side effects. Nonetheless, interferon-based therapies have the potential to cause weight loss, and literature documenting the impact of DAAs on weight is limited. Appetite suppression may occur with chronic HCV. It is plausible that DAAs may indirectly cause weight gain given their ability to cause rapid virologic suppression, leading to improved hepatic function...
December 2022: Antiviral Therapy
https://read.qxmd.com/read/36398571/letermovir-use-to-treat-complex-cytomegalovirus-reactivations-in-two-heart-transplant-recipients
#30
JOURNAL ARTICLE
Aude Boignard, Caroline Augier, Mathilde Kheng, Olivier Epaulard, Raphaele Germi
Letermovir, an anti-cytomegalovirus (CMV) drug, is recommended as a prophylactic agent in patients at risk of CMV infection/reactivation after allogeneic hematopoietic stem cell transplant. We report the curative and pre-emptive use of letermovir in two heart transplant recipients. In one patient with ganciclovir-resistant CMV, letermovir was successfully used to treat CMV colitis. In the second patient, letermovir was used as pre-emptive therapy for CMV reactivation, but did not prevent CMV esophagitis. In both cases, letermovir was successful for secondary prophylaxis...
December 2022: Antiviral Therapy
https://read.qxmd.com/read/36382358/edp-514-in-healthy-subjects-and-nucleos-t-ide-reverse-transcriptase-inhibitor-suppressed-patients-with-chronic-hepatitis-b
#31
JOURNAL ARTICLE
Jordan J Feld, Eric Lawitz, Tuan Nguyen, Jacob Lalezari, Tarek Hassanein, Paul Martin, Steven-Huy Han, Douglas Dieterich, Jeanne-Marie Giard, Guy De La Rosa, Alaa Ahmad, Ed Luo, Annie L Conery, Nathalie Adda
BACKGROUND: Chronic hepatitis B (CHB) remains a major cause of morbidity and mortality. EDP-514 is a potent core inhibitor of hepatitis B virus (HBV) that reduces viral load reduction in HBV-infected chimeric mice. This first-in-human study evaluated the safety, tolerability, and pharmacokinetics (PK) of EDP-514 in healthy subjects and antiviral activity in patients with CHB. METHODS: In Part 1, 82 subjects received placebo or EDP-514 in fed or fasted state as single ascending doses of 50-800 mg and multiple ascending doses of 200-800 mg for 14 days...
December 2022: Antiviral Therapy
https://read.qxmd.com/read/36310438/preface-special-collection-commemorating-john-c-martin
#32
EDITORIAL
Stephen Locarnini, Douglas Richman, Richard Whitley
No abstract text is available yet for this article.
October 2022: Antiviral Therapy
https://read.qxmd.com/read/36263960/antiretroviral-therapy-adherence-patterns-virological-suppression-and-emergence-of-drug-resistance-a-nested-case-control-study-from-uganda-and-south-africa
#33
JOURNAL ARTICLE
Anisha Tyagi, Yao Tong, Dustin J Rabideau, Zahra Reynolds, Tulio De Oliveira, Richard Lessells, Gideon Amanyire, Catherine Orrell, Stephen Asiimwe, Benjamin Chimukangara, Jennifer Giandhari, Sureshnee Pillay, Jessica E Haberer, Mark J Siedner
BACKGROUND: Relationships between distinct antiretroviral therapy (ART) adherence patterns and risk of drug resistance are not well understood. METHODS: We conducted a nested case-control analysis within a longitudinal cohort study of individuals initiating efavirenz-based ART. Primary outcomes of interest, measured at 6 and 12 months after treatment initiation, were: 1) virologic suppression, 2) virologic failure with resistance, and 3) virologic failure without resistance...
October 2022: Antiviral Therapy
https://read.qxmd.com/read/36191080/a-phase-1-randomized-study-of-gsk3732394-an-investigational-long-acting-biologic-treatment-regimen-for-hiv-1-infection
#34
RANDOMIZED CONTROLLED TRIAL
Mark Krystal, Shiven Chabria, Daren Austin, Allen Wolstenholme, David Wensel, Max Lataillade, Judah Abberbock, Mark Baker, Peter Ackerman
BACKGROUND: The GSK3732394 multivalent protein was developed as a novel, long-acting, antiretroviral biologic treatment regimen with three independent, non-cross-resistant mechanisms for inhibiting HIV-1 entry. METHODS: A single-centre, Phase 1, double-blind, randomized, placebo-controlled study was conducted in healthy volunteers, using a 2-part adaptive study design: in Part 1, participants were randomized to receive subcutaneous injection of GSK3732394 or placebo (3:1) as single ascending doses (10-mg starting dose); in Part 2, participants were intended to receive multiple ascending doses...
October 2022: Antiviral Therapy
https://read.qxmd.com/read/36112852/antiretroviral-therapy-achieved-metabolic-complete-remission-of-hepatic-aids-related-epstein-barr-virus-associated-smooth-muscle-tumor
#35
JOURNAL ARTICLE
Takahide Ara, Tomoyuki Endo, Hideki Goto, Kohei Kasahara, Yuta Hasegawa, Shota Yokoyama, Souichi Shiratori, Masao Nakagawa, Ken Kuwahara, Emi Takakuwa, Satoshi Hashino, Takanori Teshima
Epstein-Barr virus-associated smooth muscle tumor (EBV-SMT) is a rare mesenchymal tumor which occurs in immunocompromised patients. The immune status is an important factor in the treatment of EBV-SMTs, but the efficacy of antiretroviral therapy (ART) is not elucidated in acquired immune deficiency syndrome (AIDS) related EBV-SMTs. Here, we report the first successful case of a 29-year-old man with hepatic AIDS related EBV-SMT treated with ART solely. Positron emission tomography scan was useful for the evaluation of disease status...
October 2022: Antiviral Therapy
https://read.qxmd.com/read/36062614/pharmacokinetic-interaction-between-raltegravir-and-rifampicin-in-an-infant-with-hiv-exposed-to-active-tb-a-case-report
#36
JOURNAL ARTICLE
Marlotte Aa van der Veer, Tom G Jacobs, Laura H Bukkems, Angela Ph Colbers, David M Burger, Henriette J Scherpbier, Yuma A Bijleveld
We report a case of an infant with HIV receiving raltegravir granules for oral suspension and rifampicin-based TB prophylaxis. Raltegravir trough levels remained subtherapeutic and viral load increased during concurrent rifampicin therapy despite using double-dosed raltegravir. Even after rifampicin therapy, a higher dose was needed. This highlights the importance of therapeutic drug monitoring and dose adjustments of raltegravir in infants with rifampicin as comedication.
August 2022: Antiviral Therapy
https://read.qxmd.com/read/36000318/the-renal-bone-axis-in-older-people-living-with-hiv-on-stable-antiretroviral-therapy-a-sub-analysis-of-the-gs-us-104-0423-study
#37
JOURNAL ARTICLE
Elena Alvarez, Lucy Campbell, Willard Tinago, Alejandro Garcia-Leon, Ian Walsh, Jennifer J Brady, Keith Burling, Sebastian Noe, Marie F Neuville, Francois Jouret, Farid Jamshidian, Hiba Graham, Martin Rhee, Paddy W Mallon, Frank A Post
BACKGROUND: Data on low bone mineral density (BMD) in people living with HIV (PLWH) are mainly derived from younger adults; little is known about how antiretroviral therapy (ART) and alterations in the renal-bone axis relate to BMD in older PLWH. METHODS: Cross-sectional study of men > 50 years and post-menopausal women with HIV. Antiretroviral therapy exposure was stratified into four groups based on use of tenofovir disoproxil fumarate (TDF) and protease inhibitors (PI): non-TDF/non-PI, non-TDF/PI, TDF/non-PI, and TDF/PI...
August 2022: Antiviral Therapy
https://read.qxmd.com/read/35976773/resistance-levels-to-non-nucleoside-reverse-transcriptase-inhibitors-among-pregnant-women-with-recent-hiv-infection-in-malawi
#38
JOURNAL ARTICLE
George Bello, Matthew Kagoli, Sikhona Chipeta, Andrew Auld, Joy C-W Chang, Joshua R DeVos, Evelyn Kim, Jonathan Mkungudza, Danielle Payne, Michael Eliya, Rose Nyirenda, Andreas Jahn, Taziona Mzumara, Bernard Mvula, Sufia Dadabhai, Ireen Namakhoma, Yusuf Babaye, Amalia Giron, Michael R Jordan, Silvia Bertagnolio, Gabrielle O'Malley, Nellie Wadonda-Kabondo
BACKGROUND: Information on HIV drug resistance (HIVDR) prevalence in people newly diagnosed with HIV is limited. We implemented a cross-sectional study to estimate HIVDR prevalence among pregnant women recently infected with HIV in Malawi. METHODS: The HIVDR study was nested within a routine antenatal clinic (ANC) sentinel surveillance survey. Dried blood spot samples were tested for recent infection using a limiting antigen antibody assay together with HIV viral load testing...
August 2022: Antiviral Therapy
https://read.qxmd.com/read/35802475/progress-in-the-quality-of-care-for-newly-diagnosed-people-with-hiv-in-spain-2004-2019
#39
JOURNAL ARTICLE
Belén Alejos, Cristina Díez, María J Galindo, Juan C López, Estela Moreno-García, Vicente Estrada, Eva Poveda, Mohamed Omar, Inmaculada Jarrín, Juan Berenguer
BACKGROUND: We monitored the quality of care for newly diagnosed people with HIV (PWH) in Spain, including linkage to care within 1 month of HIV diagnosis (LC-1Mo) and viral suppression within 3 months of HIV diagnosis (VS-3Mo). METHODS: Longitudinal study based on The Cohort of the Spanish AIDS Research Network (CoRIS). We used logistic regression stratified by year of HIV diagnosis (2004-2013 and 2014-2019) to assess differences by sex, country of origin, HIV risk group, age, prior AIDS, HIV Viral Load, and CD4 cell count...
August 2022: Antiviral Therapy
https://read.qxmd.com/read/36029009/outcomes-of-etravirine-based-antiretroviral-treatment-in-treatment-experienced-children-and-adolescents-living-with-hiv-in-europe-and-thailand
#40
JOURNAL ARTICLE
European Pregnancy And Paediatric Infections Cohort Collaboration Eppicc, Alex Lyons, Lindsay Thompson, Elizabeth Chappell, Luminita Ene, Luisa Galli, Tessa Goetghebuer, Gonzague Jourdain, Antoni Noguera-Julian, Christian R Kahlert, Christoph Königs, Pope Kosalaraksa, Pagakrong Lumbiganon, Magdalena Marczyńska, Laura Marques, Marissa Navarro, Lars Naver, Liubov Okhonskaia, Filipa Prata, Thanyawee Puthanakit, Jose T Ramos, Anna Samarina, Claire Thorne, Evgeny Voronin, Anna Turkova, Carlo Giaquinto, Ali Judd, Intira J Collins
BACKGROUND: Etravirine (ETR) is approved as a component of second or third-line antiretroviral treatment (ART) for children living with HIV. We assessed the outcomes of ETR-based ART in children in routine care in Europe and Thailand. METHODS: Data on children aged <18 years at ETR start were pooled from 17 observational cohorts. Characteristics at ETR start, immunological and virological outcomes at 12 months, discontinuations, adverse events (AEs) and serious adverse events (SAEs) were described...
June 2022: Antiviral Therapy
journal
journal
20043
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.